Evidence map›Paper›PMID 32058716›Full record

ArticleJournal of the American Chemical Society2020

Macrocyclic Modalities Combining Peptide Epitopes and Natural Product Fragments.

Stéphanie M Guéret, Sasikala Thavam, Rodrigo J Carbajo, Marco Potowski, Niklas Larsson, Göran Dahl, Anita Dellsén, Tom N Grossmann, Alleyn T Plowright, Eric Valeur and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of the American Chemical Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Small-Molecule Trk Agonists: Where Do We Go from Here?Journal of medicinal chemistry · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. In Silico Analysis of Peptide Macrocycle -Protein Interactions.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Stéphanie M GuéretDepartment of Chemical Biology, AstraZeneca-Max Planck Institute Satellite Unit, Max-Planck-Institute of Molecular Physiology, 44227 Dortmund, Germany.ORCID 0000-0001-7220-9506
Sasikala ThavamDepartment of Chemical Biology, Max-Planck-Institute of Molecular Physiology, 44227 Dortmund, Germany.
Rodrigo J CarbajoChemistry, Oncology R&D, AstraZeneca, Cambridge CB2 0SL, United Kingdom.
Marco PotowskiDepartment of Chemical Biology, Max-Planck-Institute of Molecular Physiology, 44227 Dortmund, Germany.
Niklas LarssonDiscovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, 431 50 Gothenburg, Sweden.
Göran DahlStructure, Biophysics & Fragment Based Lead Generation, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, 431 50 Gothenburg, Sweden.
Anita DellsénMechanistic Biology & Profiling, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, 431 50 Gothenburg, Sweden.
Tom N GrossmannDepartment of Chemistry and Pharmaceutical Sciences, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0003-0179-4116
Alleyn T PlowrightMedicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 431 50 Gothenburg, Sweden.
Eric ValeurMedicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 431 50 Gothenburg, Sweden.ORCID 0000-0001-8270-9432
Malin LemurellMedicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 431 50 Gothenburg, Sweden.ORCID 0000-0001-8718-9421
Herbert WaldmannDepartment of Chemical Biology, Max-Planck-Institute of Molecular Physiology, 44227 Dortmund, Germany.ORCID 0000-0002-9606-7247
AstraZeneca (Sweden) · SEMax Planck Institute of Molecular Physiology · DETU Dortmund University · DEAstraZeneca (United Kingdom) · GBVrije Universiteit Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

"Hot loop" protein segments have variable structure and conformation and contribute crucially to protein-protein interactions. We describe a new hot loop mimicking modality, termed PepNats, in which natural product (NP)-inspired structures are incorporated as conformation-determining and -restricting structural elements into macrocyclic hot loop-derived peptides. Macrocyclic PepNats representing hot loops of inducible nitric oxide synthase (iNOS) and human agouti-related protein (AGRP) were synthesized on solid support employing macrocyclization by imine formation and subsequent stereoselective 1,3-dipolar cycloaddition as key steps. PepNats derived from the iNOS DINNN hot loop and the AGRP RFF hot spot sequence yielded novel and potent ligands of the SPRY domain-containing SOCS box protein 2 (SPSB2) that binds to iNOS, and selective ligands for AGRP-binding melanocortin (MC) receptors. NP-inspired fragment absolute configuration determines the conformation of the peptide part responsible for binding. These results demonstrate that combination of NP-inspired scaffolds with peptidic epitopes enables identification of novel hot loop mimics with conformationally constrained and biologically relevant structure.

Indexed as

Agouti-Related ProteinEpitopesHumansNitric Oxide Synthase Type IIPeptides, CyclicProtein BindingProtein ConformationReceptors, MelanocortinStereoisomerismSuppressor of Cytokine Signaling ProteinsAgouti-Related ProteinAGRP protein, humanEpitopesNitric Oxide Synthase Type IINOS2 protein, humanPeptides, CyclicReceptors, MelanocortinSPSB2 protein, humanSuppressor of Cytokine Signaling Proteins

Identifiers

PMID32058716
PMCPMC7307906
OpenAlexW3005548717

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.